If you purchased or acquired securities in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877 ...
Regeneron Pharmaceuticals REGN Get Free Report has outperformed the market over the past 15 years by 12.37% on an annualized ...
On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of ...
The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...
NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.
Kingsview Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 16.5% in the fourth quarter, according to the company in its most recent ...
India - Mice Not Meek Over Morality And Amendment. Legal News and Analysis - India - Intellectual Property - Conventus Law ...
Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback